Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership […]
PepsiCo, Inc. (NASDAQ: PEP) (“PepsiCo”) announced on Monday that it has entered into a definitive agreement to acquire poppi, a fast-growing prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a […]
BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement […]
Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The […]
Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to […]
Taylored Biotherapeutics, founded by UCalgary’s Dr. Valerie Taylor, MD, PhD, and supported by Chief Operating Officer Asem Bala, has achieved a significant milestone by securing a $100,000 grant from the Ontario Brain Institute (OBI). This award, part of OBI’s highly competitive Neurotech […]
Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba’s Research Services Unit (Australia and Asia) under one identity. United under […]
The new investment extends Series A investment to about $50 million Freya Biosciences, a transatlantic biotech company specializing in women’s health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation […]
Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up specializing in Adaptive Laboratory Evolution (ALE). Created in 2017, Altar will complement Lesaffre’s existing know-how […]
dsm-firmenich, innovators in nutrition, health and beauty, today announces the completion of the sale of its yeast extract business to Lesaffre, a global player in fermentation and microorganisms. The sale of the yeast extract business […]
Ostia Sciences Inc., a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, has successfully raised over CAD $1 million in its seed round and secured full intellectual property (IP) transfer […]